-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HBV-IN-22
Category | Hepatitis B Virus (HBV) |
CAS | 2338573-94-5 |
Description | HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 µM and 0.84 µM against wild-type and drug resistant HBV strains, respectively. |
Product Information
Synonyms | HBV-IN-22|CHEMBL4555299|BDBM50513194|HY-146394|CS-0498631 |
Molecular Weight | 479.66 |
Molecular Formula | C26H29N3O2S2 |
Canonical SMILES | CCN(CC)CCOC1=CC2=C(C=C1)N=C(N(C2=O)CC3=CC=CS3)SCC4=CC=CC=C4 |
Purity | ≥98% (HPLC) |
Solubility | 10 mM in DMSO |
Appearance | Solid powder |
Storage | Store at -20°C |
Complexity | 651 |
Exact Mass | 479.17011952 |
Target | IC50: 0.71 µM (wild-type HBV DNA replication), 0.84 µM (drug resistant HBV DNA replication) |
XLogP3-AA | 5.3 |